Eledon Pharmaceuticals’ (ELDN) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Eledon Pharmaceuticals (NASDAQ:ELDN – Free Report) in a report released on Tuesday, Benzinga reports. The firm currently has a $16.00 target price on the stock. Eledon Pharmaceuticals Stock Performance Eledon Pharmaceuticals stock opened at $2.78 on Tuesday. The firm has a market capitalization of $68.97 million, […]

Leave a Reply

Your email address will not be published.

Previous post PTC (NASDAQ:PTC) Given “Neutral” Rating at Mizuho
Next post Needham & Company LLC Reiterates “Buy” Rating for Lattice Semiconductor (NASDAQ:LSCC)